The AIFM2 Knockout PaTu 8988t Polyclonal Cells product comprises a polyclonal population of the human pancreatic ductal adenocarcinoma cell line PaTu 8988t that has been genetically modified via CRISPR/Cas9-mediated disruption of the AIFM2 gene. This polyclonal knockout cell population is designed to eliminate functional expression of AIFM2, providing a relevant loss-of-function model for investigating the gene’s role in apoptosis and mitochondrial biology. Unlike clonal cell lines, the polyclonal nature retains inherent genetic heterogeneity of the edited pool, which can be advantageous for studying population-level cellular responses.
The host cell line, PaTu 8988t, is an established epithelial cell line derived from a liver metastasis of a human pancreatic ductal adenocarcinoma, making it a valuable model system for pancreatic cancer research. It retains key features of aggressive pancreatic tumors, including metastatic origin and ductal phenotype, and is widely employed to study tumor progression, metastasis, and therapeutic resistance mechanisms. The cells are adherent and maintain characteristics consistent with their pancreatic origin, offering a robust platform for in vitro cancer biology studies.
AIFM2 encodes a mitochondrial flavoprotein that functions as an oxidoreductase and a key mediator of caspase-independent programmed cell death. As an apoptosis-inducing factor, AIFM2 is activated by upstream signals including p53 and reactive oxygen species (ROS), and upon pro-apoptotic stimulation it undergoes mitochondrial outer membrane permeabilization and translocates to the nucleus. There, it directly promotes chromatin condensation and large-scale DNA fragmentation, achieving cell demise independently of caspases. AIFM2 interacts with cofactors NADH and FAD, and its apoptotic function operates in parallel with canonical caspase-dependent pathways, integrating multiple stress signals to regulate cell fate.
In the PaTu 8988t pancreatic cancer context, disruption of AIFM2 is particularly relevant for exploring mechanisms that enable cancer cells to evade apoptosis. Pancreatic adenocarcinomas often exhibit profound resistance to cell death, contributing to aggressive tumor behavior and treatment failure. By removing AIFM2, researchers can examine how loss of this mitochondrial death effector alters sensitivity to chemotherapeutic agents, modulates oxidative stress responses, and possibly enhances survival signals under metabolic or genotoxic insults. This model aids in dissecting the contribution of caspase-independent pathways to overall apoptotic resistance in pancreatic cancer.
This knockout product supports a wide array of research applications, including assessment of apoptotic signaling, mitochondrial function, drug resistance mechanisms, and screening for pro-apoptotic compounds. Recommended assays for characterization include western blotting to confirm AIFM2 protein depletion, Annexin V and TUNEL assays for apoptosis detection, JC-1 or TMRE-based mitochondrial membrane potential measurements, immunofluorescence to visualize AIFM2 translocation, and RT-qPCR for transcript-level validation. Cell viability assays such as MTS can be used to evaluate treatment sensitivity. Together, these tools enable detailed mechanistic studies and preclinical drug testing. For more information, please contact Ascent Research.
